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Early signs interventions show promise but could be further developed. A recent review suggested 
that ‘basic symptoms’ should be added to conventional early signs to improve relapse prediction. This 
study builds on preliminary evidence that basic symptoms predict relapse and aimed to: 1. examine 
which phenomena participants report prior to relapse and how they describe them; 2. determine the 
best way of identifying pre-relapse basic symptoms; 3. assess current practice by comparing self- and 
casenote-reported pre-relapse experiences. 
Methods 
Participants with non-affective psychosis were recruited from UK mental health services. In-depth 
interviews (n=23), verbal checklists of basic symptoms (n=23) and casenote extracts (n=208) were 
analysed using directed content analysis and non-parametric statistical tests. 
Results 
Three-quarters of interviewees reported basic symptoms and all reported conventional early signs 
and ‘other’ pre-relapse experiences. Interviewees provided rich descriptions of basic symptoms. 
Verbal checklist interviews asking specifically about basic symptoms identified these experiences 
more readily than open questions during in-depth interviews. Only 5% of casenotes recorded basic 
symptoms; interviewees were 16 times more likely to report basic symptoms than their casenotes did. 
Conclusions 
The majority of interviewees self-reported pre-relapse basic symptoms when asked specifically about 
these experiences but very few casenotes reported these symptoms. Basic symptoms may be potent 
predictors of relapse that clinicians miss. A self-report measure would aid monitoring of basic 
symptoms in routine clinical practice and would facilitate a prospective investigation comparing basic 
symptoms and conventional early signs as predictors of relapse. 
 




Relapse of psychosis is common (Robinson et al., 1999) and predicts distress (Maclean, 2008), 
impaired vocational and interpersonal functioning (Gumley and Schwannauer, 2006), long-term 
deterioration (Wiersma et al., 1998) and suicide (Appleby, 1992). It frequently results in hospital 
admission, the single biggest expense in schizophrenia’s annual UK National Health Service cost of 
over £3.9 billion (Almond et al., 2004; Andrew et al., 2012), the USA equivalent being $22.7 billion 
(Wu et al., 2005). Interventions using early signs of deterioration to prompt timely preventative action 
can prevent relapse (Gumley et al., 2003; Herz et al., 2000; Lee et al., 2010), but could be further 
developed. Predictive validity of checklists such as the Early Signs Scale (ESS; Birchwood et al., 
1989) could be improved by adding other hypothesised predictors such as basic symptoms (Eisner et 
al., 2013; Gumley et al., 2015). 
 
‘Basic symptoms’ are subtle, sub-clinical disturbances in one’s experience of oneself and the world 
that prospectively predict first episodes of psychosis (FEP) (Fusar-Poli et al., 2012; Schultze-Lutter et 
al., 2007). Typical basic symptoms include: perceptual changes such as colours’ increased vividness; 
mild subjective cognitive problems; decreased tolerance of stressors. Overlap between lists of 
conventional early signs (e.g. ESS) and basic symptoms (e.g. Schizophrenia Proneness Index, Adult 
Version, SPI-A; Schultze-Lutter et al., 2007) is small (<5%). There is preliminary evidence that basic 
symptoms predict relapses of psychosis (Bechdolf et al., 2002; Gaebel and Riesbeck, 2014).  
 
We aimed to investigate whether basic symptoms could be used to predict relapse in routine clinical 
practice and to compare them to conventional early signs in anticipation of developing and 
prospectively testing a basic symptoms measure. Using data from in-depth interviews, verbal 
checklists of basic symptoms and casenote extracts, we addressed the following research questions: 
1. Which pre-relapse experiences (early signs, basic symptoms, ‘other’) do participants report and 
how do they describe them?; 2. What is the best way of identifying basic symptoms: in-depth 
interview or verbal checklist?; 3. Which pre-relapse experiences (early signs, basic symptoms, ‘other’) 







Ethical approval was obtained from the Liverpool Central research ethics committee (ref: 
12/NW/0091).  
 
2.2. Which pre-relapse experiences do participants report? What is the best way of identifying 
basic symptoms? 
2.2.1. Participants 
Sample A: 23 patients were purposively sampled to include a range of characteristics from three NHS 
(National Health Service) Mental Health Trusts between May and November 2012. Inclusion criteria 
were: aged over 18 years; primary clinical diagnosis of non-affective psychosis (APA, 2000); 
admission to crisis team or inpatient unit in the past 6 months for acute psychosis; prescribed 
antipsychotic medication; no illicit drug use, or alcohol abuse or dependence, during the pre-relapse 
period; informed consent. 
 
2.2.2. Data collection 
In-depth interview: open questions explored events, feelings and experiences in the three months 
prior to the most recent relapse (topic guide available on request). Verbal checklist of basic 
symptoms: assessed experiences of basic symptoms in the three months prior to the recent relapse, 
based on the SPI-A, (Schultze-Lutter et al., 2007). The SPI-A (56 items) includes two overlapping lists 
of basic symptoms that predict FEP, ‘COGDIS’ (Cognitive Disturbances, 9 items) and ‘COPER’ 
(Cognitive-Perceptive basic symptoms, 14 items), in addition to 38 other basic symptoms (Schultze-
Lutter et al., 2007). All interviews were audio-recorded and transcribed verbatim. 
 
2.3. Which pre-relapse experiences are reported in casenotes? 
2.3.1. Participants 
Sample A: 21/23 in-depth interview and verbal checklist participants consented to their casenotes 
being examined. Sample B: 187 patients (approximately 10% of those eligible) were randomly 
selected (stratified by clinical team) from those aged over 18 with a clinical diagnosis of non-affective 
psychosis (WHO, 1992) and attending Community Mental Health Teams in one NHS Mental Health 
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Trust in November 2010. Since data was obtained from a pseudo-anonymised dataset gathered for 
an audit, separate ethical approval and patient consent were not required (BMA, 2014). 
 
2.3.2. Data collection 
Five research assistants examined participants’ electronic casenotes (n=208) and extracted 
demographic information and verbatim quotations from the section of the most recent CPA review 
entitled “early warning signs”, “relapse indicators” or “crisis plan”.  
 
2.4. Analysis 
2.4.1. Directed content analysis 
Directed content analysis (Hsieh and Shannon, 2005) was used to quantify pre-relapse experiences. 
Supplementary material Section B gives details of this process. All transcripts were coded according 
to the stage of the relapse process being described (pre-relapse, during relapse, unrelated to 
relapse). Pre-relapse experiences were then coded, with codes grouped into early signs, basic 
symptoms and ‘other’ pre-relapse experiences. Inter-rater reliability was assessed (supplementary 
material Section B).  
 
2.4.2. Statistical analysis 
Non-parametric statistics were used due to the relatively small size of the interview sample (see 







3.1. Sample characteristics 
Table 1 shows demographic and clinical characteristics of the two samples.  
 
3.2. Inter-rater reliability 
Casenote data extraction: mean percentage agreement with consensus extraction was 95.7% after 
training and 91.4% during data collection. Stage-of-relapse coding: weighted kappa was 0.74. Pre-
relapse experience coding: ICCs and kappas were calculated for three types of item (early signs, 
basic symptoms, other) and three types of data (in-depth interviews, verbal checklist, casenotes). 
ICCs all exceeded 0.72 and kappa values all exceeded 0.60. 
 
3.3. Which pre-relapse experiences do participants report and how do they describe them? 
3.3.1. Estimated sensitivity (early signs, basic symptoms, ‘other’) 
Three-quarters (74%) of participants reported ≥1 basic symptom, with all participants reporting both 
conventional early signs and ‘other’ pre-relapse experiences. Sensitivity here refers to the proportion 
of relapses correctly identified by a putative predictor. Since all participants in the interview sample 
had relapsed, it equates to the proportion reporting a particular pre-relapse experience (i.e. 74% for 
basic symptoms, 100% for early signs, 100% for ‘other). No demographic or clinical characteristics 
listed in Table 1 significantly predicted reporting ≥1 basic symptom.  
 
3.3.2. Number of pre-relapse experiences reported (early signs, basic symptoms, ‘other’) 
Figure 1 shows the number of basic symptoms, early signs and ‘other’ experiences reported to begin 
or increase pre-relapse. Participants reported significantly more (z=3.12, p=0.002) early signs 
(Median=5; IQR=3,6) than they did basic symptoms (Median=2, IQR=0,5). However, 35% (6/17) of 
those reporting basic symptoms, reported at least as many basic symptoms as they did conventional 
early signs. Furthermore, reported pre-relapse experiences were idiosyncratic, with a wide range of 
experiences reported (79 experiences) and most (57%) reported by ≤2 participants. 
 
3.3.3. Estimated specificity (basic symptoms only) 
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Fourteen participants reported that they experienced basic symptoms at times unrelated to relapse 
(with no increase prior to relapse). Specificity, generally the proportion of non-cases correctly 
identified by negative test values was estimated by the proportion of the sample who did not report 
having experienced basic symptoms at times unrelated to relapse (39% for any basic symptoms; 70% 
for COGDIS; 61% for COPER).  
 
3.3.4. Estimated Receiver Operating Characteristic curve (basic symptoms only) 
Figure 2 illustrates the relative sensitivity and specificity of basic symptoms based on available data 
from the current study. Sensitivity and specificity were estimated, as described above, for any basic 
symptom, COPER basic symptoms and COGDIS basic symptoms at thresholds of 1, 2, 3, 4 and 5 
basic symptoms present. Predicting relapse using any basic symptom was more sensitive but less 
specific than using a sub-set such as COPER or COGDIS. Conversely, using a higher threshold (e.g. 
2 basic symptoms rather than 1) yielded a more specific but less sensitive assessment of imminent 
relapse. Figure 2 gives an approximation of the area within which the ROC (Receiver Operating 
Characteristic) curves may fall for the three groups of basic symptoms. Although there are no points 
close to the top left corner of the graph (which would indicate extremely good prediction of relapse), 
the points do not straddle the line either suggesting that these groups of basic symptoms do have 
some predictive value. Visual inspection gives an overall impression that using a threshold of ≥2 or ≥3 
basic symptoms, or alternatively ≥2 COPER basic symptoms, may give a better balance of sensitivity 
and specificity than using a threshold of ≥1 basic symptoms.  
 
3.3.5. How did people describe basic symptoms? 
The eighteen most frequently self-reported basic symptoms are shown in Table 2, with example 
quotations. A further 15 basic symptoms, not listed in the table, were reported by only one participant 
each. Thus 73% (33/45) of basic symptoms listed in the SPI-A were specifically identified as 
beginning or increasing during the period before relapse, rather than at other times. The quotations 
from participants (Table 2) provide rich, authentic descriptions of basic symptoms, which will be used 




3.4. What is the best way of identifying basic symptoms: in-depth interview or verbal 
checklist? 
Twice as many participants reported ≥1 basic symptom during the verbal checklist (69.6%) than 
during the in-depth interview (34.8%), a statistically significant difference (Χ
2
=6.40, p=0.022). The 
number of basic symptoms reported in the verbal checklist (Median=2, IQR=0,3) was also significantly 
higher (z=2.87, p=0.004) than in the in-depth interview (Median=0, IQR=0,1).  
 
3.5. Which pre-relapse experiences are reported in casenotes? 
Table 3 shows the percentages of participants for whom each type of pre-relapse experience (basic 
symptoms, early sign, ‘other’) was reported via self-report (in-depth interviews, verbal checklists) or in 
casenotes, and the median number of experiences reported in each case. As with the self-reported 
data, examination of individual items indicated that although a large range of pre-relapse experiences 
was reported in casenotes, half of these (34/68, 50%) were reported in ≤2 participants’ casenotes. 
 
Interviewees were significantly more likely to self-report ≥1 early sign, basic symptom or ‘other’ 
experience, respectively, than was reported in their casenotes (Table 3). The largest difference was 
for basic symptoms, with sixteen times more participants’ self-reporting basic symptoms (76.2% 
participants) than had them reported in casenotes (4.8%). The number of self-reported basic 
symptoms and ‘other’ experiences was significantly higher than in casenotes, whereas the reported 
number of early signs did not differ between self-report and casenotes (Table 3).  
 
Table 3 also compares the two study samples in terms of casenote-reported pre-relapse experiences. 
The samples did not differ in terms of the proportion reporting each type of pre-relapse experience 
(basic symptoms, early signs, ‘other’) or the number of these experiences reported. The two samples 
also did not differ in terms of gender, ethnicity or living situation (see Table 1), but the non-interview 
sample (B: n=187) was significantly older and more likely to have high levels of family contact than 
the interview sample (A: n=23). Thus, the two samples were largely comparable, with significant 






This study used 23 in-depth interview transcripts, 23 verbal checklist transcripts and 208 casenote 
extracts to: i) examine which basic symptoms occurred prior to relapse; ii) how these basic symptoms 
were described in order to compare spontaneous and prompted self-reported symptoms; and iii) 
compare self-reported experiences to those assessed in clinical practice. Three-quarters of 
participants retrospectively reported ≥1 basic symptom that began or increased prior to a recent 
relapse. All participants reported ≥1 conventional early sign and ‘other’ pre-relapse experience. 
Although participants reported significantly more early signs than they did basic symptoms, a third of 
participants who reported basic symptoms reported as many as they did conventional early signs. 
Participants gave rich descriptions of basic symptoms, but only when prompted. 
 
Basic symptoms have been shown to predict FEP in continental European samples (Fusar-Poli et al., 
2012; Schultze-Lutter et al., 2007). Only two previous studies (Bechdolf et al., 2002; Gaebel and 
Riesbeck, 2014) have investigated whether basic symptoms occurred prior to relapse in those with 
established psychosis. A small, retrospective study (Bechdolf et al., 2002) found basic symptoms 
reported prior to both depressive and psychotic episodes, with differences in the content of basic 
symptoms distinguishing a depressive from a psychotic episode. Unlike the current study, only those 
with ICD-10 paranoid schizophrenia who had no residual symptoms were included in the psychosis 
sample, which limits the generalizability of the findings. More recently, a larger study (Gaebel and 
Riesbeck, 2014) appears to have prospectively assessed basic symptoms in those with a previous 
episode of psychosis. Although the authors do not explicitly state that they examined basic symptoms, 
they list ten items whose brief descriptions resemble the COPER sub-scale of the SPI-A. Sensitivity 
(mean 12%) and specificity (mean 97%) values for these 10 individual items provide some evidence 
that basic symptoms occur prior to relapse. However, since no combined predictive value for the 
COPER-like items is given, one cannot draw strong conclusions about the value of basic symptoms 
as predictors of relapse. 
 
The current study shows that one can identify pre-relapse basic symptoms in a UK sample of patients 
with chronic schizophrenia. Although the current retrospective study cannot determine definitively how 
well basic symptoms predict relapse, it does indicate that it is a question worth further investigation. A 
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prospective study comparing the sensitivity and specificity of basic symptoms and conventional early 
signs is warranted. Data from the current study will inform the development of a definitive prospective 
study in three specific ways: i) it will help to determine the threshold number (and type) of basic 
symptoms required to count someone as a ‘case’ (i.e. predicted to have a relapse; see section 4.1.1.);  
ii) it will inform the design of a self-report measure for prospectively monitoring basic symptoms (see 
section 4.1.2.); iii) it lends weight to the idea that monitoring an individualised ‘relapse signature’ is the 
most efficient way of spotting early indicators of relapse (given the wide range and idiosyncratic 
nature of reported pre-relapse experiences; see section 4.1.3.). 
 
Estimated retrospective sensitivity of reporting ≥1 basic symptom (74%) in the current study was 
higher than the median prospective sensitivity (61%) of early signs measures in a recent review 
(Eisner et al., 2013), but estimated specificity was lower (current study, 39%; review median, 81%). 
This suggests that using ≥1 basic symptom is not the optimum threshold for caseness. Although there 
was insufficient data to perform a formal ROC analysis with probability testing, we plotted a 
descriptive ROC curve to explore whether setting a higher threshold for caseness (e.g. ≥3 basic 
symptoms) or defining a smaller, more predictive set of basic symptoms (e.g. COGDIS or COPER) 
would provide a better balance of sensitivity and specificity. Visual inspection of the ROC curve 
suggested that a threshold of ≥2 or ≥3 basic symptoms, or alternatively ≥2 COPER basic symptoms, 
may give a better balance of sensitivity and specificity.  
 
To monitor basic symptoms as part of a personalised relapse signature, clinicians need to identify 
which of these an individual experienced prior to previous relapses. The best way of identifying pre-
relapse basic symptoms in the current study was a verbal checklist asking specifically about these 
experiences: twice as many participants identified basic symptoms during verbal checklists than 
during in-depth interviews. Firstly, this may be because the in-depth interview required recall memory 
whereas the verbal checklist only used recognition memory, the latter being easier (Speer and Flavell, 
1979) and both being impaired in schizophrenia (Libby et al., 2013). Secondly, unlike psychotic 
symptoms, patients are not commonly asked about basic symptoms in a UK mental health service 
context. Aside from a small number of Early Intervention Services assessing basic symptoms as 
prodromal symptoms of FEP (e.g. Lancashire Early Assessment and Detection Clinic; Johnson, 
 11 
 
2013), we know of very few clinical services in the UK who assess them. Participants in the current 
study (all receiving care from UK mental health services) may not have spontaneously divulged these 
experiences because they did not expect the interviewer to be interested in them. Thirdly, patients 
may not recognise the experiences as ‘symptoms’ per se and only begin to think their experience is 
unusual when asked about them. Fourthly, some basic symptoms may not be spontaneously divulged 
due to embarrassment, whereas being asked as part of a checklist, framed as a list of experiences 
that people sometimes report before relapse, may normalise the experience.  
 
The casenote data gives an insight into which pre-relapse experiences are assessed in current 
practice. Only 5% of casenotes contained ≥1 basic symptom, with participants sixteen times more 
likely to self-report a basic symptom than the casenotes. This was as predicted: basic symptoms are 
not currently enquired about in British psychiatry, especially not as early indicators of relapse, and 
clinicians are not generally trained to assess them. Furthermore, basic symptoms are subtle and 
subjective, without outward signs that they are occurring, and patients tend not to disclose them until 
prompted.  
 
This study used directed content analysis to quantify the number of basic symptoms, early signs and 
‘other’ experiences reported during in-depth interviews, verbal checklists and in casenotes. Although 
the coding method was systematic, it was necessary for the coder to use judgement at times. 
Nevertheless inter-rater reliability, assessed in 10% of cases, was generally high. For all statistical 
analyses, findings were considered significant at p=0.05. Using a different threshold for significance 
may have resulted in different conclusions. There are limitations specific to the self-reported data. 
Firstly, the sample for this data was relatively small and purposively rather than randomly selected. 
We used non-parametric statistics to account for the resultant non-normality of the data and 
compared the purposive sample to a much larger, randomly selected sample. Since the two samples 
were largely comparable, it is likely that the purposive sample provides a fairly good representation of 
the experiences of this patient group. Secondly, data was gathered retrospectively, which may have 
introduced bias; to minimise this, only patients who had relapsed in the past six months were 
interviewed. Thirdly, inherent in all studies where any two measures are used serially, the first 
measure could prime the second. We aimed to minimize this effect by doing the in-depth interview, 
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with its open questions, first and the verbal checklist of basic symptoms second. Fourthly, there were 
limitations of the descriptive ROC curve (Figure 2) and the specificity data upon which it is based. 
There was insufficient data to perform a formal ROC analysis with probability testing; the estimates of 
specificity are likely to be biased since they were based on incidental reports during assessments 
aiming to elicit pre-relapse experiences. Where high specificity is shown, this may be due to lack of 
data rather than a genuinely highly specific assessment.  
 
In summary, most interviewees self-reported pre-relapse basic symptoms but very few casenotes 
reported them. Basic symptoms may be potent predictors of relapse that clinicians miss. The best 
way of identifying pre-relapse basic symptoms was a verbal checklist asking specifically about these 
experiences. Use of a basic symptoms checklist in clinical practice, in conjunction with an existing 
checklist of conventional early signs, may yield a richer relapse signature. A prospective study 
examining whether adding basic symptoms to conventional early signs of relapse enhances predictive 
value is warranted. A self-report measure of basic symptoms could facilitate such a prospective 
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